CRMD vs MRNA: Which Is the Better Buy in 2026?
Last updated October 2026
Short answer
MRNA is the larger of the two ($87.04B market cap): the incumbent the market prices for continued execution (-49.13x forward earnings, beta 1.10). CRMD is the smaller challenger ($565.88M), priced similarly on forward earnings (20.74x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CRMD vs MRNA: the tie-breaker metrics
Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CRMD | MRNA | What it tells you |
|---|---|---|---|
| Market cap | $565.88M | $87.04B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 20.74 | -49.13 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.41 | 1.10 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 16% of range | 89% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.22 | 12.87 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CRMD and MRNA affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRMD and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRMD and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does CorMedix (CRMD) do?
CorMedix is a New Jersey-based pharmaceutical company whose lead product, DefenCath (taurolidine and heparin), is the first and only FDA-approved antimicrobial catheter lock solution in the United States. It prevents catheter-related bloodstream infections in adult hemodialysis patients who use a central venous catheter, a population where infections drive costly hospitalizations and mortality, and a Phase III study showed up to a 71% reduction in infection risk. After a 2023 approval, commercialization scaled quickly through multi-year agreements that now cover roughly 60% of the U.S. outpatient dialysis market, and DefenCath generated about ~$167.6M in 2025 sales.
What does Moderna (MRNA) do?
Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.
CRMD vs MRNA: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CRMD drivers: DefenCath adoption in outpatient dialysis; Melinta platform diversification.
- MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue is still heavily concentrated in DefenCath, so any adoption, contracting, or clinical setback would hit the whole story. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.
CRMD or MRNA: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CRMD if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRMD and MRNA guides.
CRMD vs MRNA: the full fundamentals
CRMD. CorMedix looks very cheap on trailing numbers, about 3.6 times earnings and roughly 1.2 times sales, but those figures include quarters that benefited from TDAPA add-on payments. Forward estimates tell a different story, with a loss expected in the third quarter of 2026 and 2027 EPS near $0.06, which is why the stock trades near 21 times forward earnings and fell about 40% this year. Analysts remain constructive, with a mean target near $15.3 and Oppenheimer initiating at outperform with a $15 target in September.
MRNA. MRNA trades on pipeline potential rather than current earnings: it is loss-making, revenue is far below its pandemic peak, and P/E is not meaningful. What changed in 2026 is the price of that option, with the stock up about 590% year to date to roughly 38 times trailing sales after the August Phase 3 melanoma success. The 18 analysts Yahoo Finance tracks have a mean target near $124, well under the $213 close, so the detailed data later in October and the November 6 Q3 report (consensus revenue near $892 million, EPS near -$1.30) carry unusual weight.
Headline figures (approximate, October 2026): CRMD shows revenue (ttm) ~$462M; Q2 2026 ~$102M, up ~156% YoY, eps (q2 2026) ~$0.29 vs ~$0.24 consensus, net income (ttm) ~$186M, a profit margin near ~40%, fy2026 adjusted ebitda guidance ~$125M-$140M (raised after Q2); MRNA shows market cap ~$85 billion, revenue (ttm) ~$2.2 billion, q2 2026 revenue ~$145 million, net income (ttm) ~-$3.2 billion.
The bottom line: CRMD vs MRNA
CRMD and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRMD and MRNA exposure against your real portfolio. It is not an investment adviser.
Wondering how CRMD or MRNA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in CorMedix with AI
Connect the broker you already use and ask Walnut's AI how CRMD fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CRMD and MRNA?
+
CorMedix is a New Jersey-based pharmaceutical company whose lead product, DefenCath (taurolidine and heparin), is the first and only FDA-approved antimicrobial catheter lock solution in the United States. Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CRMD or MRNA the better stock?
+
Neither is universally better. MRNA is the larger incumbent; CRMD is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CRMD or MRNA?
+
On forward P/E (as of October 2026), CRMD trades at 20.74x and MRNA at -49.13x, so MRNA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CRMD and MRNA?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CRMD vs MRNA?
+
CRMD: Revenue is still heavily concentrated in DefenCath, so any adoption, contracting, or clinical setback would hit the whole story. The product benefited from early reimbursement support such as the Transitional Drug Add-On Payment (TDAPA), and those benefits are expiring, which could pressure pricing and margins as dialysis reimbursement normalizes. Competition is a latent threat: established players such as Amphastar could extend anticoagulant or lock-solution capabilities into the catheter-infection market. The Melinta portfolio carries integration risk and includes mature products with their own competitive and reimbursement dynamics. As a small-cap healthcare name, the shares are volatile and sensitive to policy, payer, and single-quarter execution swings: they fell about 40% in 2026 through October 16. Consensus estimates point to a third-quarter loss on revenue near $53 million, and analysts expect full-year 2027 EPS near $0.06, far below 2026, which shows how much the post-TDAPA reset weighs on earnings. A final ESRD reimbursement rule was expected in November 2026. MRNA: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed. Valuation risk is now acute: at about $85 billion the company trades near 38 times trailing sales, analysts are split (Goldman Sachs raised its target to $137 with a Neutral rating, Morgan Stanley is at $95, Citi has a Sell and an $80 target, all below the October 16 price), and the stock fell about 9% in a single day on October 16 as profit-taking set in. A disappointing detailed readout of the melanoma data could reverse much of the gain. Walnut is not an investment adviser.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CRMD or MRNA; figures are approximate and dated (as of October 2026). Verify current data before investing.